AMPH
VENTE TOTALE: 16 153 titres (~345 738,30 $ US)
- Insiders
- PRINS RICHARD K, PETERS WILLIAM J
- Total bought
- —
- Total sold
- $345,738
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-14
Despite a strong liquidity buffer (current ratio 4.02, score 85), AMPH's deteriorating fundamentals — net margin compression from 21.8% to 13.6% YoY, declining ROE, and weakening interest coverage — drag the fundamental…
The first sentence of the analysis written for AMPH on 2026-08-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | |
| Ebit Margin | 20.7% | 30.1% | 30.8% | 23.6% | 19.4% | |
| Ebitda Margin | 29.5% | 37.9% | 37.3% | 29.3% | 25.5% | |
| Operating Profit Margin | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | |
| Pretax Profit Margin | 17.2% | 25.8% | 26.3% | 23.0% | 19.2% | |
| Continuous Operations Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.5% | |
| Net Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | |
| Bottom Line Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | |
| Current Ratio | 4.021 | 3.074 | 2.172 | 3.988 | 3.064 | |
| Quick Ratio | 2.903 | 2.189 | 1.703 | 2.896 | 2.170 | |
| Solvency Ratio | 0.192 | 0.256 | 0.205 | 0.561 | 0.392 | |
| Cash Ratio | 1.076 | 0.873 | 0.640 | 1.646 | 1.217 | |
| Price To Earnings Ratio | 12.752 | 11.286 | 21.702 | 14.904 | 17.915 | |
| Price To Earnings Growth Ratio | -0.353 | 0.731 | 0.421 | 0.334 | 0.004 | |
| Forward Price To Earnings Growth Ratio | -0.353 | 0.731 | 0.421 | 0.334 | 0.004 | |
| Price To Earnings Diluted Ratio | 13.192 | 12.134 | 23.788 | 16.103 | 18.632 | |
| Price To Earnings Diluted Growth Ratio | -0.392 | 0.686 | 0.481 | 0.411 | 0.004 | |
| Price To Book Ratio | 1.587 | 2.456 | 4.669 | 2.573 | 2.498 | |
| Price To Sales Ratio | 1.739 | 2.457 | 4.633 | 2.726 | 2.542 | |
| Price To Free Cash Flow Ratio | 10.325 | 10.434 | 20.540 | 20.882 | 15.775 | |
| Price To Operating Cash Flow Ratio | 8.018 | 8.427 | 16.268 | 15.254 | 11.355 | |
| Debt To Assets Ratio | 0.403 | 0.412 | 0.412 | 0.138 | 0.156 | |
| Debt To Equity Ratio | 0.832 | 0.888 | 0.975 | 0.194 | 0.235 | |
| Debt To Capital Ratio | 0.454 | 0.470 | 0.494 | 0.163 | 0.190 | |
| Long Term Debt To Capital Ratio | 0.436 | 0.451 | 0.480 | 0.121 | 0.143 | |
| Financial Leverage Ratio | 2.066 | 2.154 | 2.366 | 1.404 | 1.507 | |
| Working Capital Turnover Ratio | 1.718 | 2.344 | 2.353 | 2.005 | 2.293 | |
| Operating Cash Flow Ratio | 0.987 | 1.228 | 0.814 | 0.940 | 0.944 | |
| Operating Cash Flow Sales Ratio | 0.217 | 0.292 | 0.285 | 0.179 | 0.224 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.777 | 0.808 | 0.792 | 0.731 | 0.720 | |
| Debt Service Coverage Ratio | 6.887 | 8.099 | 7.555 | 25.078 | 29.455 | |
| Interest Coverage Ratio | 5.510 | 6.770 | 7.253 | 58.232 | 78.968 | |
| Short Term Operating Cash Flow Coverage Ratio | 95.134 | 911.906 | 420.878 | 29.278 | 44.502 | |
| Operating Cash Flow Coverage Ratio | 0.238 | 0.328 | 0.294 | 0.869 | 0.936 | |
| Capital Expenditure Coverage Ratio | 4.476 | 5.199 | 4.808 | 3.711 | 3.569 | |
| Dividend Paid And Capex Coverage Ratio | 4.476 | 5.199 | 4.808 | 3.711 | 3.569 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.184 | 8.283 | 14.418 | 8.941 | 9.780 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 49.5% | ▼-1.6% | ▼-0.6% |
| Ebit Margin | 20.7% | ▼-9.4% | ▼-4.2% |
| Ebitda Margin | 29.5% | ▼-8.4% | ▼-2.4% |
| Operating Profit Margin | 19.5% | ▼-8.6% | ▼-3.6% |
| Pretax Profit Margin | 17.2% | ▼-8.7% | ▼-5.1% |
| Continuous Operations Profit Margin | 13.6% | ▼-8.2% | ▼-4.3% |
| Net Profit Margin | 13.6% | ▼-8.2% | ▼-4.2% |
| Bottom Line Profit Margin | 13.6% | ▼-8.2% | ▼-4.2% |
| Current Ratio | 4.021 | ▲0.948 | ▲0.757 |
| Quick Ratio | 2.903 | ▲0.714 | ▲0.531 |
| Solvency Ratio | 0.192 | ▼-0.065 | ▼-0.130 |
| Cash Ratio | 1.076 | ▲0.203 | ▼-0.014 |
| Price To Earnings Ratio | 12.752 | ▲1.467 | ▼-2.959 |
| Price To Earnings Growth Ratio | -0.353 | ▼-1.084 | ▼-0.580 |
| Forward Price To Earnings Growth Ratio | -0.353 | ▼-1.084 | ▼-0.580 |
| Price To Earnings Diluted Ratio | 13.192 | ▲1.058 | ▼-3.578 |
| Price To Earnings Diluted Growth Ratio | -0.392 | ▼-1.078 | ▼-0.630 |
| Price To Book Ratio | 1.587 | ▼-0.869 | ▼-1.169 |
| Price To Sales Ratio | 1.739 | ▼-0.718 | ▼-1.080 |
| Price To Free Cash Flow Ratio | 10.325 | ▼-0.108 | ▼-5.266 |
| Price To Operating Cash Flow Ratio | 8.018 | ▼-0.408 | ▼-3.846 |
| Debt To Assets Ratio | 0.403 | ▼-0.010 | ▲0.098 |
| Debt To Equity Ratio | 0.832 | ▼-0.057 | ▲0.207 |
| Debt To Capital Ratio | 0.454 | ▼-0.016 | ▲0.100 |
| Long Term Debt To Capital Ratio | 0.435 | ▼-0.015 | ▲0.110 |
| Financial Leverage Ratio | 2.066 | ▼-0.089 | ▲0.166 |
| Working Capital Turnover Ratio | 1.718 | ▼-0.626 | ▼-0.425 |
| Operating Cash Flow Ratio | 0.987 | ▼-0.241 | ▲0.004 |
| Operating Cash Flow Sales Ratio | 0.217 | ▼-0.075 | ▼-0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.777 | ▼-0.031 | ▲0.011 |
| Debt Service Coverage Ratio | 6.886 | ▼-1.212 | ▼-8.528 |
| Interest Coverage Ratio | 5.510 | ▼-1.260 | ▼-25.837 |
| Short Term Operating Cash Flow Coverage Ratio | 95.134 | ▼-816.772 | ▼-205.206 |
| Operating Cash Flow Coverage Ratio | 0.238 | ▼-0.090 | ▼-0.295 |
| Capital Expenditure Coverage Ratio | 4.476 | ▼-0.724 | ▲0.123 |
| Dividend Paid And Capex Coverage Ratio | 4.476 | ▼-0.724 | ▲0.123 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8.184 | ▼-0.099 | ▼-1.737 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.25B | $1.80B | $2.99B | $1.36B | $1.11B | |
| Enterprise value | $1.74B | $2.30B | $3.46B | $1.31B | $1.09B | |
| EV / Sales | 2.41x | 3.14x | 5.38x | 2.62x | 2.49x | |
| EV / Op. cash flow | 11.13x | 10.77x | 18.88x | 14.65x | 11.13x | |
| EV / Free cash flow | 14.33x | 13.33x | 23.84x | 20.06x | 15.47x | |
| EV / EBITDA | 8.18x | 8.28x | 14.42x | 8.94x | 9.78x | |
| Net debt / EBITDA | 2.29x | 1.80x | 2.00x | -0.37x | -0.19x | |
| Current ratio | 4.02x | 3.07x | 2.17x | 3.99x | 3.06x | |
| Income quality | 1.59x | 1.34x | 1.33x | 0.98x | 1.55x | |
| Graham number | $28 | $33 | $29 | $21 | $17 | |
| Graham net-net | -$8 | -$9 | -$10 | $2 | $0 | |
| Tax burden | 79.3% | 84.3% | 81.2% | 79.6% | 74.0% | |
| Interest burden | 82.9% | 86.0% | 85.3% | 97.4% | 98.7% | |
| Working capital | $477.9M | $360.3M | $264.2M | $283.5M | $214.3M | |
| Invested capital | $1.40B | $1.30B | $1.19B | $585.3M | $524.7M | |
| Return on assets | 6.0% | 10.1% | 9.1% | 12.3% | 9.2% | |
| Operating ROA | 8.8% | 13.3% | 17.5% | 15.2% | 10.7% | |
| Return on tangible assets | 9.2% | 16.2% | 15.3% | 13.0% | 9.8% | |
| Return on equity | 12.4% | 21.8% | 21.5% | 17.3% | 13.9% | |
| Return on invested capital | 7.5% | 12.3% | 12.4% | 13.1% | 9.2% | |
| Return on capital employed | 9.5% | 14.6% | 15.3% | 16.6% | 12.3% | |
| Earnings yield | 7.8% | 8.9% | 4.6% | 6.7% | 5.6% | |
| Free cash flow yield | 9.7% | 9.6% | 4.9% | 4.8% | 6.3% | |
| Capex / Op. cash flow | 22.3% | 19.2% | 20.8% | 26.9% | 28.0% | |
| Capex / Depreciation | 55.2% | 71.7% | 91.4% | 83.6% | 102.6% | |
| Capex / Sales | 4.8% | 5.6% | 5.9% | 4.8% | 6.3% | |
| SG&A / Sales | 18.0% | 12.9% | 12.5% | 13.3% | 15.7% | |
| R&D / Sales | 11.9% | 10.1% | 11.4% | 15.0% | 13.9% | |
| Stock comp / Sales | 3.8% | 3.3% | 3.1% | 3.6% | 4.3% | |
| Intangibles / Total assets | 34.7% | 37.4% | 40.5% | 5.0% | 5.8% | |
| Days sales outstanding | 73d | 69d | 65d | 65d | 66d | |
| Days payables outstanding | 33d | 31d | 32d | 30d | 34d | |
| Operating cycle | 250d | 226d | 197d | 216d | 208d | |
| Cash conversion cycle | 218d | 194d | 165d | 186d | 174d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-30.4%EV / Sales ▼-23.1%EV / EBITDA ▼-1.2%EV / Op. cash flow ▲+0.365Earnings yield ▼-0.010Graham number ▼-5.248
Profitability
Return on equity ▼-0.093Return on assets ▼-0.041Return on invested capital ▼-0.048Return on capital employed ▼-0.051Operating ROA ▼-0.045Income quality ▲+0.254Tax burden ▼-0.050
Efficiency
Days sales outstanding ▲+3.956Days payables outstanding ▲+1.596Operating cycle ▲+24.717Cash conversion cycle ▲+23.121Capex / Sales ▼-0.008R&D / Sales ▲+0.018
Balance-sheet strength
Current ratio ▲+0.948Net debt / EBITDA ▲+0.489Working capital ▲+117548000.000Invested capital ▲+101945000.000Intangibles / Total assets ▼-0.027
Change over 5 years
Valuation
Market cap ▲+12.5%EV / Sales ▼-3.2%EV / EBITDA ▼-16.3%EV / Op. cash flow ▼-0.003Earnings yield ▲+0.023Graham number ▲+11.712
Profitability
Return on equity ▼-0.015Return on assets ▼-0.032Return on invested capital ▼-0.017Return on capital employed ▼-0.028Operating ROA ▼-0.020Income quality ▲+0.043Tax burden ▲+0.053
Efficiency
Days sales outstanding ▲+7.084Days payables outstanding ▼-1.367Operating cycle ▲+42.230Cash conversion cycle ▲+43.596Capex / Sales ▼-0.014R&D / Sales ▼-0.020
Balance-sheet strength
Current ratio ▲+0.957Net debt / EBITDA ▲+2.483Working capital ▲+263551000.000Invested capital ▲+872874000.000Intangibles / Total assets ▲+0.289
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-14 New Strong Sell Stocks for August 14th AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
- 2026-08-07 Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
- 2026-08-06 Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-06 Amphastar Pharmaceuticals Q2 Earnings Call Highlights Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
- 2026-08-06 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
- 2026-07-29 Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
- 2026-07-22 Trump''s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
- 2026-06-23 New Strong Sell Stocks for June 23rd ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
- 2026-06-10 Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.
- 2026-06-08 Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors'' losses and whether they may be recovered under federal securities laws.